PDCD1 and cancer: A series of clinical studies showed that anti-PD-1/PD-L1 antibodies had robust and durable anti-cancer activities across several solid and hematologic cancers, such as lung cancer [7–9], renal cell cancer [10], melanoma [11], hepatocellular carcinoma [12], as well as lymphoma [13–15].